SCHEMBL2268362

SCHEMBL2268362

COC(=O)c1ccc(OCCCc2ccccc2)cc1NC(=O)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.54
KDM4E B2RXH2 8/20 0.53
HSD17B10 Q99714 2/20 0.53
MAPK1 P28482 1/20 0.53
ALDH1A1 P00352 6/20 0.50
HPGD P15428 4/20 0.50
MAPT P10636 3/20 0.50
LMNA P02545 3/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TSHR P16473 1/20 0.47
EHMT2 Q96KQ7 1/20 0.47
PLK1 P53350 3/20 0.47
POLB P06746 2/20 0.46
PLK3 Q9H4B4 1/20 0.46
GAA P10253 2/20 0.46
ELANE P08246 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2269617 0.94 KDM4E (0.54) NR1H4KDM4EHSD17B10MAPK1ALDH1A1
SCHEMBL2273929 0.90 NR1H4 (0.60) NR1H4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2277733 0.87 KDM4E (0.64) NR1H4KDM4EHSD17B10MAPK1ALDH1A1
SCHEMBL14428936 0.85 FFAR1 (0.48) KDM4EMAPTRAB9AMEN1KMT2A
SCHEMBL9856719 0.84 FFAR1 (0.60) NR1H4PLK1PLK3
SCHEMBL2272635 0.83 MCL1 (0.55) NR1H4MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL2269238 0.81 KDM4E (0.68) NR1H4KDM4EHSD17B10MAPK1ALDH1A1
SCHEMBL4833752 0.81 MCHR1 (0.51) KDM4EHSD17B10MAPK1ALDH1A1HPGD
SCHEMBL7909139 0.81 MAOB (0.56) MEN1KMT2ATSHR
SCHEMBL7908891 0.79 FFAR4 (0.56) KDM4EHPGDLMNANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 NR1H4 2482/4885KDM4E 1257/4885HSD17B10 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.